Dr. Lal Path Labs Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI depositories regulations for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The diagnostic services company filed its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 on April 09, 2026. Company Secretary and Compliance Officer Vinay Gujral submitted the documentation to both the National Stock Exchange of India Limited and BSE Limited.

RTA Confirmation Certificate

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, serves as the company's Registrar & Share Transfer Agent. The RTA issued its confirmation certificate on April 6, 2026, which was subsequently enclosed with Dr. Lal PathLabs' regulatory filing.

Swapan Kumar Naskar, Associate Vice President & Head of the Delhi Branch at MUFG Intime India, confirmed that during the quarter ended March 31, 2026, the RTA did not receive any demat requests for processing. The certificate specifically noted that Dr. Lal PathLabs does not maintain any physical shares.

Corporate Structure Details

The filing included standard corporate identification details for both exchanges. Dr. Lal PathLabs trades on NSE under the symbol LALPATHLAB and on BSE with scrip code 539524. MUFG Intime India Private Limited operates under CIN U67190MH1999PTC118368 and functions as part of MUFG Corporate Markets, a division of MUFG Pension & Market Services.

This quarterly compliance filing represents routine regulatory adherence, ensuring transparency in share transfer and dematerialization processes as mandated by SEBI regulations for listed companies.

Dr. Lal PathLabs Limited has announced a scheduled board meeting on April 30, 2026, to review and approve the company's audited financial results for the fourth quarter and full financial year ending March 31, 2026. The announcement was communicated to stock exchanges through a regulatory filing dated March 27, 2026.

Board Meeting Details

The meeting of the Board of Directors is specifically scheduled to consider and approve both standalone and consolidated audited financial results. This regulatory disclosure was made under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring compliance with mandatory disclosure requirements.

Trading Window Closure

In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's internal Code for Prevention of Insider Trading, Dr. Lal PathLabs has announced a trading window closure. This restriction will be effective from April 1, 2026, to May 2, 2026, with both days inclusive.

Regulatory Compliance and Exchange Communication

The notification was formally communicated to both major stock exchanges where the company's shares are listed. The communication was addressed to the National Stock Exchange of India Limited at Exchange Plaza, Bandra Kurla Complex, and BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street. The official filing referenced the company's trading symbols - LALPATHLAB on NSE and scrip code 539524 on BSE.

The filing was digitally signed by Vinay Gujral, Company Secretary & Compliance Officer, ensuring proper authorization and compliance with regulatory requirements. This scheduled board meeting represents a routine corporate governance practice, allowing the board to review and formally approve the company's financial performance for the concluded financial year and quarter before public disclosure.